RS
NBIX icon

Rakuten Securities’s Neurocrine Biosciences NBIX Stock Holding History

Rakuten Securities’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85K Sell
11
-2
-15% -$297 ﹤0.01% 661
2026
Q1 		$1.71K Buy
13
+8
+160% +$1.06K ﹤0.01% 631
2025
Q4 		$709 Sell
5
-4
-44% -$579 ﹤0.01% 721
2025
Q3 		$1.26K Sell
9
-17
-65% -$2.3K ﹤0.01% 684
2025
Q2 		$3.27K Sell
26
-17
-40% -$1.95K ﹤0.01% 545
2025
Q1 		$4.76K Buy
43
+12
+39% +$1.52K ﹤0.01% 498
2024
Q4 		$4.23K Buy
31
+30
+3,000% +$3.71K ﹤0.01% 502
2024
Q3 		$115 Sell
1
-1
-50% -$137 ﹤0.01% 683
2024
Q2 		$275 Sell
2
-23
-92% -$3.15K ﹤0.01% 638
2024
Q1 		$3.45K Sell
25
-3
-11% -$410 ﹤0.01% 438
2023
Q4 		$3.69K Buy
+28
New +$3.22K ﹤0.01% 380

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rakuten Securities's NBIX Position: Q2 2026 in Review

Rakuten Securities reduced its Neurocrine Biosciences (NBIX) stake by 15% in Q2 2026, selling an estimated $297 and leaving 11 shares worth $1.85K. The position accounts for ﹤0.01% of the portfolio, ranked #661.

Rakuten Securities first reported a position in NBIX in Q4 2023 and has held it in 11 quarters since. The position peaked at $4.76K in Q1 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Rakuten Securities held 11 shares of Neurocrine Biosciences worth $1.85K as of Q2 2026.
  • Rakuten Securities sold 2 Neurocrine Biosciences shares in Q2 2026, an estimated $297.
  • Neurocrine Biosciences made up ﹤0.01% of Rakuten Securities's portfolio in Q2 2026, its #661 holding.
  • Rakuten Securities first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 11 quarters since.
  • Rakuten Securities's Neurocrine Biosciences position peaked at $4.76K in Q1 2025.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Rakuten Securities's 13F filing for Q2 2026, filed 12 Aug 2026.